And this brings up something I have always struggled with. I know the biotech space well. I know even a two bit company with promise just in phase I can be sold for a bottom price of $250M. I kind of expected to see something similar here with CTSO, not to be sold but a decent market cap by now, but it does not seem to be the way with medical device companies.
For those who have invested more in medical device companies versus biotech, is it typical for potential company value to lag for device companies whereas more value is placed on the potential in a biotech company? Is it there is more competition to buy the best biotech opportunity whereas in the device arena people are not scrambling over each other?
If Cytosorb was the name of a small molecule that does what the filter does, then the valuation of this company would be like PCYC today, not CTSO today. Just look what people were paying for non approved HCV drugs, and how some have already failed! Bewilders me a little looking at the potential for cytosorb as to how this is a $25M market cap company.